HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas Podsadecki Selected Research

paritaprevir

7/2017Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
6/2016Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
4/2016Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
3/2015Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
2/2015Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.
8/2014ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
5/2014ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
5/2014ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
4/2014Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
1/2014Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas Podsadecki Research Topics

Disease

14Infections
07/2017 - 01/2013
8Fibrosis (Cirrhosis)
07/2017 - 01/2014
5Chronic Hepatitis C
12/2017 - 07/2013
4Hepatitis C
04/2016 - 01/2013
4Body Weight (Weight, Body)
05/2014 - 01/2014
2Coinfection
04/2016 - 03/2015
1Virus Diseases (Viral Diseases)
12/2017
1Anemia
06/2016
1Chronic Kidney Failure (Chronic Renal Failure)
06/2016
1Chronic Renal Insufficiency
06/2016
1HIV Infections (HIV Infection)
04/2016
1Drug-Related Side Effects and Adverse Reactions
01/2016

Drug/Important Bio-Agent (IBA)

13Ribavirin (Virazole)FDA LinkGeneric
07/2017 - 01/2013
12paritaprevirIBA
07/2017 - 01/2013
12dasabuvirIBA
07/2017 - 01/2013
12Ritonavir (Norvir)FDA Link
07/2017 - 01/2013
11InterferonsIBA
01/2016 - 01/2013
10Antiviral Agents (Antivirals)IBA
12/2017 - 01/2013
10ombitasvirIBA
07/2017 - 01/2014
5Protease Inhibitors (Protease Inhibitor)IBA
08/2014 - 01/2013
3telaprevirIBA
01/2016 - 04/2014
1glecaprevir and pibrentasvirIBA
12/2017
1ErythropoietinFDA Link
06/2016
1Pharmaceutical PreparationsIBA
04/2016
1Human immunodeficiency virus 1 p16 proteaseIBA
04/2016
1Rilpivirine (TMC-278)IBA
01/2016
1Raltegravir PotassiumFDA Link
03/2015
1RNA (Ribonucleic Acid)IBA
03/2015
1Atazanavir Sulfate (Reyataz)FDA Link
03/2015
1dimemorfan (AT 17)IBA
03/2015
1NucleosidesIBA
08/2014
1TabletsIBA
04/2014
1PlacebosIBA
04/2014

Therapy/Procedure

8Therapeutics
12/2017 - 01/2013
1Renal Dialysis (Hemodialysis)
06/2016
1Aftercare (After-Treatment)
02/2015
1Retreatment
04/2014